<DOC>
	<DOCNO>NCT00516191</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability four dose level liposomal doxorubicin , melphalan , bortezomib patient relapsed/refractory MM identify maximum tolerate dose ( MTD ) combination .</brief_summary>
	<brief_title>A Phase I/II Study Liposomal Doxorubicin ( Doxil ) /Melphalan/Bortezomib ( Velcade ) Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Previously diagnose multiple myeloma ; DurieSalmon Stage I , II , III base standard criterion Progressive disease , define 25 % increase serum Mprotein Bence Jones protein ( absolute increase 0.5 gram/dL serum Mprotein least 200 mg/24 hour urine light chain excretion ) . For nonsecretory multiple myeloma , progressive disease define bone marrow biopsy &gt; 25 % increase plasma cell absolute increase least 10 % prior know level . Alternatively , development new worsen exist lytic bone lesion soft tissue plasmacytoma , hypercalcemia relapse CR . 18 year old willing able comply protocol requirement . Patient sign informed consent . Unless female patient postmenopausal surgically sterilize , must willing use acceptable method birth control ( hormonal contraceptive , intrauterine device , diaphragm , spermicide , condom spermicide , abstinence ) duration study . Male patient must agree use acceptable method contraception duration study . ECOG performance Status &lt; equal 2 . Life expectancy least 3 month . Initial Required Laboratory Values within 14 day baseline i.e . Cycle 1 , Day 1 ( note renal insufficiency , include dialysis dependence permissable ) : ANC &gt; 1,000uL without use colony stimulate factor Platelets &gt; 50,000/L without transfusion support 7 day test Bilirubin &lt; equal 2.0 mg/dL AST &lt; equal 4 x upper limit normal Prior therapy : Patient must least 2 prior therapeutic regimen define treatment multiple myeloma Biologic therapy : Prior nonmyeloablative transplantation allow provided patient significant graftversushost disease aggressive immunosuppressive therapy least 30 day . Low dose immunosuppression allow ( i.e . Prednisone dose &lt; equal 10 mg daily , low dose tacrolimus ( subtherapeutic level ) agent equivalent lowdose immunosuppression ) . Chemotherapy : Mobilization chemotherapy follow either single tandem autologous transplantation count 1 prior regimen . Mobilization chemotherapy follow autologous subsequent nonmyeloablative allogenic transplantation count 1 prior regimen . Any combination drug give concurrently count single regimen . Pregnant breastfeed History allergic reaction compound contain boron mannitol . Active uncontrolled viral ( include HIV ) , bacterial , fungal infection . Grade III IV toxicity due previous antineoplastic therapy ( except alopecia ) . Grade &gt; equal 2 motor sensory neuropathy define NCI Common Toxicity Criteria ( NCI CTC ) : Grade 2 : Either mild objective weakness objective sensory loss/parasthesia ( include tingle ) interfere function , interfere ADLs . Grade 3 : Objective weakness sensory loss/parasthesia interfere ADLs . Grade 4 : Paralysis permanent sensory loss interfere function . Myocardial infarction within 6 month enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled arrhythmia , electrocardiographic evidence acute ischemia . For patient whose lifetime cumulative doxorubicin dose exceeds 400 mg/m ( 2 ) , patient LVEF &lt; equal 35 % MUGA exclude . In patient , MUGA require perform , LVEF must &gt; equal 35 % . Concurrent administration liposomal doxorubicin , melphalan , bortezomib ( single two drug combination permissable ) . Less 3 week since recent chemotherapy concurrent chemotherapy . Use corticosteroid ( &gt; 10 mg prednisone/day equivalent ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Velcade</keyword>
	<keyword>Doxil</keyword>
	<keyword>Melphalan</keyword>
</DOC>